The state of Pennsylvania currently has 12 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
03/15/2024
Locations: Clinical Research Associates Of Central PA , LLC, DuBois, Pennsylvania +3 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/13/2024
Locations: Local Institution - 0334, Philadelphia, Pennsylvania +2 locations
Conditions: Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania +5 locations
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: Penn State Milton S. Hershey Medical Center/Penn State College of Medicine, Hershey, Pennsylvania +3 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/29/2024
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/23/2024
Locations: Saint Luke's University Hospital - Bethlehem, Bethlehem, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Recruiting
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/04/2024
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/24/2023
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purposes of this study are: to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pulmonary Fibrosis
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Michelle F MacPherson, Pittsburgh, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Recruiting
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date. Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity. The experimental therapy here (therapeutic plasma exchange plus... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
08/04/2023
Locations: Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Recruiting
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
07/11/2023
Locations: Temple University Medical Center, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis